ACVR2A and neoplasm: Fat loss was recently shown to play an important role in promoting cachexia and increased mortality in pancreatic cancer patients [171] and might therefore contribute to the finding that ACVR2 blockade did not improve survival in high-activin tumor-bearing mice despite maintenance of body mass [146].